Tikcro Technologies Announces Results of BioCancell Therapeutics' US FDA Phase I/IIa Pancreatic Cancer Trial

Published: Nov 02, 2010

TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTC BB: TIKRF) today announced that BioCancell reported results from a Phase I/IIa clinical trial to establish the safety, optimal dose and preliminary efficacy of BioCancell's lead drug-candidate, BC-819, as a treatment for pancreatic cancer. The trial demonstrated a significant decrease in local pancreatic tumors and no appearance of metastatic disease in most patients treated with the higher of two dosages tested after one month and three months.

Back to news